Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski, Seng‐Ryong Woo, Yuanyuan Zha, et al.
Current Opinion in Immunology (2013) Vol. 25, Iss. 2, pp. 268-276
Closed Access | Times Cited: 397

Showing 1-25 of 397 citing articles:

Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman
Immunity (2013) Vol. 39, Iss. 1, pp. 1-10
Open Access | Times Cited: 5711
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature (2017) Vol. 541, Iss. 7637, pp. 321-330
Closed Access | Times Cited: 4291
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng‐Ryong Woo, Mercedes B. Fuertes, Leticia Corrales, et al.
Immunity (2014) Vol. 41, Iss. 5, pp. 830-842
Open Access | Times Cited: 1537
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1519
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 3, pp. 151-167
Closed Access | Times Cited: 1423
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W.L. Teng, Shin Foong Ngiow, Antoni Ribas, et al.
Cancer Research (2015) Vol. 75, Iss. 11, pp. 2139-2145
Open Access | Times Cited: 1309
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales, Laura Hix Glickman, Sarah M. McWhirter, et al.
Cell Reports (2015) Vol. 11, Iss. 7, pp. 1018-1030
Open Access | Times Cited: 1269
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Hélène Salmon, Juliana Idoyaga, Adeeb Rahman, et al.
Immunity (2016) Vol. 44, Iss. 4, pp. 924-938
Open Access | Times Cited: 1021
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 6, pp. 365-379
Closed Access | Times Cited: 870
m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer
Bo Zhang, Qiong Wu, Ben Li, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 787
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shabnam Shalapour, Michael Karin
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3347-3355
Open Access | Times Cited: 629
Opportunities and challenges of radiotherapy for treating cancer
Dörthe Schaue, William H. McBride
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 9, pp. 527-540
Open Access | Times Cited: 601
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J.M. Kim, Daniel S. Chen
Annals of Oncology (2016) Vol. 27, Iss. 8, pp. 1492-1504
Open Access | Times Cited: 543
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke, Riyue Bao, Randy F. Sweis, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 10, pp. 3074-3083
Open Access | Times Cited: 541
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi, Dechao Jiao, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 500
Regulatory circuits of T cell function in cancer
Daniel E. Speiser, Ping‐Chih Ho, Grégory Verdeil
Nature reviews. Immunology (2016) Vol. 16, Iss. 10, pp. 599-611
Closed Access | Times Cited: 497
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Thomas F. Gajewski
Seminars in Oncology (2015) Vol. 42, Iss. 4, pp. 663-671
Open Access | Times Cited: 441
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping, Ashley V. Menk, Ryan D. Whetstone, et al.
Cancer Immunology Research (2016) Vol. 5, Iss. 1, pp. 9-16
Open Access | Times Cited: 434
Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer
Xiaopin Duan, Christina Chan, Nining Guo, et al.
Journal of the American Chemical Society (2016) Vol. 138, Iss. 51, pp. 16686-16695
Open Access | Times Cited: 426
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
Edmund K. Moon, Liang-Chuan Wang, Douglas V. Dolfi, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 16, pp. 4262-4273
Open Access | Times Cited: 374
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 374
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Viktor Umansky, C Blattner, Christoffer Gebhardt, et al.
Vaccines (2016) Vol. 4, Iss. 4, pp. 36-36
Open Access | Times Cited: 365
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych, Ute Hoch, John L. Langowski, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 3, pp. 680-690
Open Access | Times Cited: 361
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 24, pp. 5453-5459
Open Access | Times Cited: 330
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
Matthew B. Schabath, E A Welsh, William J. Fulp, et al.
Oncogene (2015) Vol. 35, Iss. 24, pp. 3209-3216
Open Access | Times Cited: 325
Page 1 - Next Page

Scroll to top